HB 309 Florida House · 2026 Regular Session

Controlled Substances

Summary

Controlled Substances; Excepts from list of Schedule I controlled substances certain xylazine animal drug products approved by United States Food & Drug Administration & used for certain purposes; provides criminal penalties & requires mandatory minimum term of imprisonment if person sells, manufactures, or delivers or possesses with intent to sell, manufacture, or deliver xylazine; creates offense of trafficking in xylazine; provides criminal penalties & requires mandatory minimum term of imprisonment & fines based on quantity of controlled substance involved in offense.

Issues: ✗ Criminal Justice

Bill status in committee 1 of 4 stages cleared

Introduction

Nov 2025

Committee Review

Floor Vote

Governor

Introduced Nov 4, 2025 Last action Mar 9, 2026

Maddy AI version diff · 2 comparisons

What changed between versions

H 309 c1 → H 309 c2 · 3 edits

MINOR

The bill was reclassified from a House bill to a Conference Committee version, indicating it has been reconciled with Senate amendments. The primary substantive change is the removal of a provision that would have added 7-Hydroxymitragynine (a specific concentration of kratom extract) to the list of Schedule I controlled substances. The bill now focuses exclusively on amending the statute to exclude certain FDA-approved xylazine animal drug products from criminal penalties, rather than expanding the list of banned hallucinogens.

Scope change

The bill's scope was narrowed by removing the addition of 7-Hydroxymitragynine to the list of controlled substances. The applicability of the law regarding xylazine remains focused on excluding specific FDA-approved veterinary products from criminal liability.

SCOPE

The specific provision adding 7-Hydroxymitragynine concentrated above 400 parts per million to Schedule I controlled substances was deleted.

ENFORCEMENT

The bill text was updated to reflect that the only change to the controlled substances list is the exception for certain FDA-approved xylazine animal drug products.

TECHNICAL

The bill header was updated from 'CS/HB 309' to 'CS/CS/HB 309' to indicate it is a conference committee version, and page counts were adjusted.

Floor votes

How they voted

No floor votes recorded yet.

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Feb 24, 2026

Lower · Passed

Reported out of Judiciary Committee

lower

Feb 24, 2026

Lower · Passed

Favorable by Judiciary Committee

lower

Feb 20, 2026

Lower · Passed

Added to Judiciary Committee agenda

lower

Feb 13, 2026

Lower · Passed

Now in Judiciary Committee

lower

Feb 13, 2026

Committee

Referred to Judiciary Committee

lower

Feb 12, 2026

Lower · Passed

Reported out of Justice Budget Subcommittee

lower

Feb 12, 2026

Lower · Passed

Favorable with CS by Justice Budget Subcommittee

lower

Feb 10, 2026

Lower · Passed

PCS added to Justice Budget Subcommittee agenda

lower

Jan 21, 2026

Lower · Passed

Now in Justice Budget Subcommittee

lower

Jan 21, 2026

Committee

Referred to Judiciary Committee

lower

Jan 21, 2026

Committee

Referred to Justice Budget Subcommittee

lower

Jan 20, 2026

Lower · Passed

Reported out of Criminal Justice Subcommittee

lower

Jan 20, 2026

Lower · Passed

Favorable with CS by Criminal Justice Subcommittee

lower

Jan 15, 2026

Lower · Passed

Added to Criminal Justice Subcommittee agenda

lower

Nov 12, 2025

Lower · Passed

Now in Criminal Justice Subcommittee

lower

Nov 12, 2025

Committee

Referred to Judiciary Committee

lower

Nov 12, 2025

Committee

Referred to Justice Budget Subcommittee

lower

Nov 12, 2025

Committee

Referred to Criminal Justice Subcommittee

lower

2 primary · 4 co-sponsors